This content is machine translated Immunosuppression in prostate cancer New therapeutic targets are being explored What is certain: The survival prognosis of metastatic castration-resistant prostate cancer (mCRPC) has improved – on average from just over one (before 2000) to almost three years [1]. Nevertheless, current…
View Post 4 min This content is machine translated Immuno-Oncology New pathways for improved cancer treatment? Long-term survival of patients with advanced-stage carcinoma is still an area where research is far from successful. In the field of melanoma, the approval of ipilimumab in 2011 has made…
View Post 6 min This content is machine translated 5th Interdisciplinary Prostate Cancer Symposium Metastatic prostate cancer – New therapeutic options Prostate cancer is the most common male tumor in Western countries and is the second leading cause of cancer-related death in Switzerland. In particular, metastatic castration-resistant prostate cancer (mCRPC) is…
